公开(公告)号：US20210024619A1

公开(公告)日：2021-01-28

申请号：US16640819

申请日：2018-08-22

Applicant: GRIFFITH UNIVERSITY

Inventor： Michael F. GOOD ,  Manisha PANDEY ,  Michael Raymond BATZLOFF

IPC: C07K16/12 ,  A61K9/00 ,  A61K38/16

Abstract: A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A Streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 5 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.

公开(公告)号：US20230382981A1

公开(公告)日：2023-11-30

申请号：US18201595

申请日：2023-05-24

Applicant: GRIFFITH UNIVERSITY

Inventor： Michael F. GOOD ,  Manisha PANDEY ,  Michael Raymond BATZLOFF

IPC: C07K16/12 ,  A61K9/00 ,  A61K38/16 ,  A61K39/116 ,  A61K39/09 ,  A61K47/64

CPC classification number: C07K16/1271 ,  A61K9/0019 ,  A61K38/16 ,  A61K39/116 ,  A61K39/092 ,  A61K47/646 ,  C07K14/315

Abstract: A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.